Frequently asked questions
The COVID-19 pandemic had a detrimental effect on the human insulin market. Individuals with chronic illnesses, such as diabetes, have experienced a significant emergency and routine clinical care disruptions.
North America was the largest revenue contributor to the global human insulin market in 2022.
The industry is primarily driven by rising rates of health problems like obesity, shifting consumer lifestyles, increased research and development spending on advanced insulin injection mechanisms, and the accessibility of safety pen devices and needles for optimal human insulin delivery.
The drugs segment had a major share in the global market in 2022.
The benchmark hedging segment had a major share in the global market.